The estimated Net Worth of Venture Partners Qualified ... is at least 3.58 百万$ dollars as of 29 May 2012. Venture Qualified owns over 284,698 units of Acelrx Pharmaceuticals Inc stock worth over 3,579,262$ and over the last 14 years Venture sold ACRX stock worth over 0$.
Venture has made over 1 trades of the Acelrx Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Venture bought 284,698 units of ACRX stock worth 967,973$ on 29 May 2012.
The largest trade Venture's ever made was buying 284,698 units of Acelrx Pharmaceuticals Inc stock on 29 May 2012 worth over 967,973$. On average, Venture trades about 142,349 units every 0 days since 2011. As of 29 May 2012 Venture still owns at least 4,161,933 units of Acelrx Pharmaceuticals Inc stock.
You can see the complete history of Venture Qualified stock trades at the bottom of the page.
Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over 25,363,406$ worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth 26,783,172$ . The most active insiders traders include Advisors Llcperceptive Life...、Advisors Llcedelman Josephp...、Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of 109,939$. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth 7,300$.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: